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1 The human P2Y11 (hP2Y11) receptor was stably expressed in two cell lines, 1321N1 human
astrocytoma cells (1321N1-hP2Y11) and Chinese hamster ovary cells (CHO-hP2Y11), and its
coupling to phospholipase C and adenylyl cyclase was assessed.
2 In 1321N1-hP2Y11 cells, ATP promoted inositol phosphate (IP) accumulation with low mM
potency (EC50=8.5+0.1 mM), whereas it was 15 fold less potent (130+10 mM) in evoking cyclic
AMP production.
3 In CHO-hP2Y11 cells, ATP promoted IP accumulation with slightly higher potency
(EC50=3.6+1.3 mM) than in 1321N1-hP2Y11 cells, but it was still 15 fold less potent in promoting
cyclic AMP accumulation (EC50=62.4+15.6 mM) than for IP accumulation. Comparable dierences
in potencies for promoting the two second messenger responses were observed with other adenosine
nucleotide analogues.
4 In 1321N1-hP2Y11 and CHO-hP2Y11 cells, down regulation of PKC by chronic treatment with
phorbol ester decreased ATP-promoted cyclic AMP accumulation by 60 ± 80% (P50.001) with no
change in its potency. Likewise, chelation of intracellular Ca2+ decreased ATP-promoted cyclic
AMP accumulation by *45% in 1321N1-hP2Y11 cells, whereas chelation had no eect on either the
ecacy or potency of ATP in CHO-hP2Y11 cells.
5 We conclude that coupling of hP2Y11 receptors to adenylyl cyclase in these cell lines is much
weaker than coupling to phospholipase C, and that activation of PKC and intracellular Ca2+
mobilization as consequences of inositol lipid hydrolysis potentiates the capacity of ATP to increase
cyclic AMP accumulation in both 1321N1-hP2Y11 and CHO-hP2Y11 cells.
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Introduction
P2Y receptors are heptahelical, G protein-coupled receptors
activated by extracellular nucleotides. These receptors are
expressed in almost all cells and tissues, where they regulate
a wide range of physiological processes. To date, ®ve
subtypes of P2Y receptors have been cloned in humans
(hP2Y1,2,4,6,11) (North & Barnard, 1997; Harden, 1998; King
et al., 1998). The unambiguous association of a P2Y
receptor subtype with a speci®c physiological eect has
proven dicult to establish, in part due to the lack of
subtype-selective agonists and antagonists. Thus, the phar-
macological selectivities of these receptors have been de®ned
by expressing individual subtypes of cloned P2Y receptors in
null cell lines and determining the rank order of potencies of
the natural agonists ATP, ADP, UTP and UDP, and with
nucleotide analogues.
The hP2Y1 receptor is highly selective for ADP and ATP
and their 2-methylthio derivatives (Schachter et al., 1996;
Leon et al., 1997; Palmer et al., 1998). The triphosphate-
preferring hP2Y2 receptor is activated by both UTP and
ATP with essentially equal potency, whilst ADP and UDP
have little or no eect (Lustig et al., 1993; Nicholas et al.,
1996). UTP is a potent full agonist at the hP2Y4 receptor,
whereas ADP and UDP have little or no eect (Nguyen et
al., 1995; Communi et al., 1996a; Nicholas et al., 1996).
Recently, we demonstrated that ATP is a competitive
antagonist at the hP2Y4 receptor, but is a potent full
agonist at the rat P2Y4 receptor (Kennedy et al., 2000).
The hP2Y6 receptor is a pyrimidine-preferring receptor,
with UDP more potent than UTP. ADP is a low potency
agonist whereas ATP has no eect (Nicholas et al., 1996;
Communi et al., 1996b; Li et al., 1998). Finally, the hP2Y11
receptor is highly selective for ATP (Communi et al., 1997;
1999).
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All hP2Y receptor subtypes cloned to date are linked to
activation of phospholipase C, generation of inositol
phosphates (IPs), activation of protein kinase C (PKC) and
release of intracellular Ca2+ stores. In addition to coupling to
phospholipase C, the hP2Y11 receptor also couples to
adenylyl cyclase, resulting in increased cyclic AMP synthesis
(Communi et al., 1997; 1999). ATP was reported to activate
adenylyl cyclase with similar (Communi et al., 1997) or
greater potency (Communi et al., 1999) compared to
activation of phospholipase C. However, these second
messenger assays were carried out in dierent cell lines
expressing the hP2Y11 receptor, i.e., 1321N1 human astro-
cytoma cells for IP accumulation and CHO-K1 cells for
cyclic AMP accumulation. Given that agonist potencies are
greatly in¯uenced by the level of receptor reserve (Kenakin,
1997; Palmer et al., 1998), the eciency at which the hP2Y11
receptor activates phospholipase C compared to adenylyl
cyclase remains unestablished. Thus, the aim of this study
was to determine the eciency with which the hP2Y11
receptor couples to these two second messenger pathways in
the same cell line and to determine the eects of intracellular
Ca2+ mobilization and phospholipase C activation on
activation of adenylyl cyclase. A preliminary account of
these results has been published (Kennedy et al., 1999).
Methods
PCR amplification of the coding sequence of the
hP2Y11 receptor
PCR primers complementary to the published sequence of the
hP2Y11 receptor (Communi et al., 1997) were used to amplify
the coding sequence from 0.24 mg of human genomic DNA
with Amplitaq DNA polymerase. The primers contained at
their 5' ends either an EcoRI restriction site (5'-AGA-
GAATTCCACCATGGATCGAGGTGCCAAGTCCTGCC-
CT-3'; upstream primer) or a XhoI restriction site (5'-
GAGCTCGAGTCATTGGCTCAGCTCACGG-3'; down-
stream primer). In addition, the upstream primer also
contained a consensus Kozak translation initiation consensus
sequence (CACCATGG; Kozak, 1986) preceding the start
ATG codon, all nine coding bases of exon 1 and the ®rst 18
bases of exon 2, whilst the downstream primer contained the
®nal 16 coding bases of exon 2 and the stop codon. The
ampli®cation conditions were 948C for 3 min; 35 cycles of
948C for 30 s, 568C for 30 s, 728C for 70 s; and 7 min at
728C. The ampli®ed product was puri®ed, digested with
EcoRI and XhoI, and ligated into the similarly digested
retroviral expression vector, pLXSN. Individual clones
encoding the receptor were sequenced using the Amplicycle
Sequencing Kit, and the sequence obtained was identical to
that reported by Communi et al. (1997), except for the
presence of a C in place of a T at position 240. This dierence
was found in clones originating from separate ampli®cation
reactions; however, it did not alter the protein sequence.
Expression of hP2Y11 and hD1 receptors in 1321N1 and
CHO-K1 cells
Recombinant retroviral particles were produced by calcium
phosphate-mediated transfection of PA317 packaging cells
with the pLXSN vector (Miller & Rosman, 1989; GenBank
accession no. M28248) containing hP2Y11 cDNA (Comstock
et al., 1997). 1321N1 human astrocytoma cells and CHO-K1
cells were grown in monolayer culture at 378C in 5% CO2 in
high-glucose Dulbecco's modi®ed Eagle's medium (DMEM)
supplemented with 5% fetal bovine serum (10% for CHO-K1
cells), 100 units ml71 penicillin, 0.1 mg ml71 streptomycin
and 0.25 mg ml71 amphotericin B. Cells were infected with
retrovirus harbouring the hP2Y11 coding sequence or with
control retrovirus. CHO-K1 cells were pretreated with the
glycosylation inhibitor tunicamycin (0.3 mg ml71) for 19 h
prior to infection to inhibit the production of endogenous
factors that suppress infection of hamster cells (Miller &
Miller, 1992; 1993). Geneticin-resistant cells were selected for
2 (1321N1 cells) to 4 (CHO-K1 cells) weeks with medium
containing 1 mg ml71 G-418 and were then maintained in
medium containing 0.4 mg ml71 G-418.
The human D1-dopamine receptor (GenBank accession no.
X55760) was ampli®ed by PCR from human genomic DNA
under similar conditions as above with the following primers:
up primer, 5'-AGAGAATTCACCATGCACCATG-3' and
down primer, 5'-GAGCTCGAGTCAGGTTGGGTGCT-
GACCGT-3'. Primers incorporated either an EcoRI (up-
stream primer) or XhoI (downstream primer) restriction site
to facilitate cloning. The ampli®ed receptor sequence was
cloned into the EcoRI and XhoI sites of pLXSN and
sequenced. Retroviral particles were prepared as described
above and used to generate a stable population of expressing
1321N1 cells. Radioligand binding analysis with [3H]-
SCH22799 indicated that the hD1 receptor was expressed at
*200 fmol mg71 (data not shown).
IP and cyclic AMP formation
1321N1 and CHO-K1 cells stably expressing the hP2Y11
receptor (1321N1-hP2Y11 and CHO-hP2Y11 cells, respec-
tively) were seeded in 24-well plates at either 16105 or
56104 cells per well, respectively, and assayed 3 days later
when con¯uent. Inositol lipids were radiolabelled by
incubation of the cells for 22 h with 200 ml inositol-free,
serum-free DMEM high glucose and 0.4 mCi myo-[3H]-
inositol in a humidi®ed CO2 incubator. No changes of
medium were made subsequent to the addition of [3H]-
inositol. Agonists were added in 50 ml of a 5 fold
concentrated solution in 50 mM LiCl, 250 mM HEPES,
pH 7.4. Following a 5 min incubation at 378C, the medium
was aspirated and the assay terminated by adding 0.75 ml of
boiling 10 mM EDTA, pH 8.0. [3H]-IPs were resolved by
Dowex AG1-X8 columns as described previously (Lazar-
owski et al., 1995).
To monitor cyclic AMP accumulation, the medium was
replaced 2 h before the assay with 200 ml serum-free DMEM
containing 0.8 mCi of [3H]-adenine. Control experiments, in
which cells in 200 ml serum-free DMEM high glucose for 22 h
were labelled by adding 0.8 mCi [3H]-adenine in 10 ml directly
to the medium 2 h before the assay, indicated that changing
the medium 2 h before the assay had no eect on nucleotide-
promoted cyclic AMP accumulation. No changes in medium
were made subsequent to the addition of [3H]-adenine.
Twenty minutes before the assay, HEPES buer, pH 7.4,
was added to 50 mM, followed 10 min later by addition of
200 mM IBMX (®nal concentration) in 50 mM HEPES buer,
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pH 7.4, to inhibit the hydrolysis of cyclic AMP by
phosphodiesterases. Agonists were added in 50 ml of a 6 fold
concentrated solution in Hank's balanced salt solution
(without Ca2+, Mg2+). Where indicated, cells were treated
with the phorbol ester PMA (1 mM) for either 20 h to down-
regulate PKC or for 10 min to activate PKC prior to
challenge with agonists. For chelation of intracellular [Ca2+],
cells were treated for 10 min with 50 mM BAPTA-AM prior
to challenge with agonists. Control experiments con®rmed
that this concentration of BAPTA-AM was sucient to
prevent agonist-promoted increases in intracellular [Ca2+].
Following a 10 min incubation at 378C, the assay was
terminated by aspirating the medium and adding 1 ml ice-
cold trichloroactetic acid. [3H]-cyclic AMP was isolated on
Dowex and alumina columns as described previously (Harden
et al., 1982).
Statistics
Data in the text are expressed as the mean+s.d. for EC50
values. Concentration-response curves were ®tted to the data
by logistic (Hill equation), non-linear regression analysis
(GraphPad Prism, San Diego, U.S.A.). Data were compared
as appropriate by Student's paired t-test or by one-way
analysis of variance and Tukey's comparison, with P50.05
considered to be statistically signi®cant.
Materials
AmpliTaq DNA polymerase and the Amplicycle Sequencing
Kit were obtained from Perkin-Elmer (Norfolk, CT,
U.S.A.). All tissue culture reagents and Hank's balanced
salt solution were supplied by the Lineberger Comprehen-
sive Cancer Center tissue culture facilities (University of
North Carolina at Chapel Hill, NC, U.S.A.). ATP was
purchased from Pharmacia (Piscataway, NJ, U.S.A.), ADP
was from Roche Biochemicals (Indianapolis, IN, U.S.A.),
2MeSATP, 2MeSADP, ATPgS, ADPbS and forskolin were
from RBI (Natick, MA, U.S.A.), PMA and BAPTA-AM
were from Calbiochem (La Jolla, CA, U.S.A.) and PGE1,
IBMX, and dopamine were from Sigma (St. Louis, MO,
U.S.A.). Stock solutions of ADP and 2MeSADP (10 mM)
were incubated with 50 U ml71 hexokinase (Roche Bio-
chemicals, Indianapolis, IN, U.S.A.) in DMEM high
glucose medium for 2 h before use to eliminate triphos-
phate contamination. In addition, assay solutions contained
5 U hexokinase ml71. Similarly, stock solutions (10 mM in
DMEM high glucose) of the nucleotidase-resistant nucleo-
tide analogues, ATPgS and ADPbS, were treated with
3 U ml71 apyrase (Sigma-Aldrich, St. Louis, MO, U.S.A.)
for 30 min before use.
Results
Properties of the hP2Y11 receptor expressed in
1321N1 cells
1321N1 cells infected with viruses produced from pLXSN
vector alone showed no responses to ATP (data not
shown). ATP increased IP accumulation in a concentra-
tion-dependent manner (EC50=8.5+0.1 mM) in 1321N1 cells
expressing the hP2Y11 receptor (Figure 1). At higher
concentrations, ADP also promoted IP accumulation, but
only to levels *35% of those achieved with maximal
concentrations of ATP (basal subtracted). ATP also
promoted cyclic AMP accumulation, with an EC50 of
130+10 mM (Figure 1). Thus, in 1321N1-hP2Y11 cells, ATP
promotes IP accumulation with 15 fold greater potency
than it promotes cyclic AMP accumulation. In contrast to
its ability to promote IP accumulation, ADP did not
increase cyclic AMP levels in these cells. Concentration-
response curves for ATP-promoted cyclic AMP accumula-
tion (Figures 1 ± 4) were steep. The reason(s) for this
deviation from law of mass interaction at a single site has
not been pursued.
Effects of ATP in CHO-K1 cells expressing the
hP2Y11 receptor
To ensure that cell-speci®c dierences do not account for the
dierential sensitivity of ATP in promoting the two second
messenger responses, we also expressed the hP2Y11 receptor
in CHO-K1 cells. CHO-K1 cells express a P2Y2 receptor that
responds to ATP (Iredale & Hill, 1993), but expression of the
hP2Y11 receptor in these cells gave rise to ATP-promoted
increases in IP accumulation 20 fold higher than those in
vector-infected cells (Figure 2A). This allowed us to address
the issue of dierential coupling of the hP2Y11 receptor in an
additional cell line.
In CHO-hP2Y11 cells, ATP increased IP accumulation in a
concentration-dependent manner and with a potency slightly
greater than in 1321N1-hP2Y11 cells (EC50=3.6+1.3 mM)
(Figure 2B; Table 1). ATP also evoked cyclic AMP synthesis
with a potency greater than in 1321N1 cells (EC50=
62+16 mM), but still 15 fold less than the EC50 for inositol
lipid hydrolysis. Thus, similar dierences in coupling of the
hP2Y11 receptor to adenylyl cyclase and phospholipase C
were observed in two cell lines, strongly suggesting that these
dierences are an inherent property of the receptor. ADP
promoted inositol lipid hydrolysis (EC50=50.1+20.6 mM) to
Figure 1 Concentration-response curves of ATP and ADP for
increasing IP and cyclic AMP levels in 1321N1-hP2Y11 cells. Each
point is the mean response from three experiments. Vertical lines
indicate s.d. mean.
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levels *50% of that of the maximal levels promoted by ATP
(Figure 2B). In contrast to 1321N1-hP2Y11 cells, ADP
increased cyclic AMP levels in CHO-hP2Y11 cells, although
the concentration-response curve did not reach a clear
maximum.
Coupling efficiency of the hP2Y11 receptor activated with
other adenine nucleotides
To determine whether other hP2Y11 agonists also exhibited
dierences in potency for promotion of IP and cyclic
AMP accumulation, concentration-response curves of
several adenine nucleotide analogues, including ATPgS,
ADPbS, 2MeSATP, and 2MeSADP, were generated. All of
these nucleotide analogues were considerably more potent
(7 ± 20 fold) for promotion of IP accumulation than cyclic
AMP accumulation (Table 1). The rank order of potency
of these agonists for stimulation of IP accumulation
(ATPgS42MeSATP4ATP*ADPbS42MeSADP4ADP) is
similar to that previously reported for the hP2Y11 receptor
(ATPgS4ATP4ADPbS42MeSATP; Communi et al.,
1999) with the exception of 2MeSATP, which had a
higher potency relative to the other agonists in the present
experiments.
Effects of phosphodiesterase inhibitors on
hP2Y11 receptor signalling
These data dier from those reported by Communi et al.
(1997; 1999), in which ATP was either equipotent or even
more potent for stimulating cyclic AMP accumulation
compared with IP production. One possible explanation of
this discrepancy is that in the present study IBMX was used
to inhibit cyclic AMP breakdown by phosphodiesterase, but
rolipram was employed by Communi et al. (1997). To test the
possibility that IBMX, an antagonist at adenosine receptors
(Bruns et al., 1986; Ukena et al., 1986; Con & Spealman,
1989), also acts as an antagonist at the hP2Y11 receptor, we
included 200 mM IBMX in the incubation medium during IP
assays. However, its inclusion had no eect on the ability of
Figure 2 Concentration-response curves of ATP and ADP for
increasing IP and cyclic AMP levels in CHO-hP2Y11 cells. (A)
Concentration-response curves for ATP-promoted IP production in
CHO-K1 cells infected with empty retrovirus (pLXSN) or with
retrovirus harbouring hP2Y11 receptor cDNA (P2Y11). (B) Concen-
tration-response curves of ATP and ADP for increasing IP and cyclic
AMP levels in CHO-hP2Y11 cells. Each point is the mean response
from ®ve experiments. Vertical lines indicate s.d. mean.
Figure 3 Eects of Ca2+ chelation and PKC down-regulation on
ATP-promoted cyclic AMP accumulation in 1321N1-hP2Y11 cells.
(A) Cells treated with BAPTA-AM (50 mM) for 10 min, PMA (1 mM)
for 20 h, or a combination of both were challenged with buer or
300 mM ATP and cyclic AMP accumulation was measured as
described in Methods. (B) 1321N1 cells expressing the hD1 dopamine
receptor were treated as described in (A), challenged with 100 mM
dopamine for 10 min, and cyclic AMP accumulation was measured.
(C) Concentration-response curves of ATP for promotion of cyclic
AMP accumulation in vehicle- or PMA- (1 mM for 20 h) plus
BAPTA-AM- (50 mM for 10 min) treated 1321N1-hP2Y11 cells. Data
shown are the mean+s.d. of triplicate assays from a representative
experiment repeated three times. **P40.01 and ***P40.001 relative
to control response. {{P40.01 relative to PMA treatment alone.
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ATP to evoke IP synthesis (data not shown), indicating that
IBMX is not an antagonist at the hP2Y11 receptor and its use
does not underlie the discrepancy between the present study
and those of Communi et al. (1997; 1999).
Influence of PKC activation and intracellular Ca2+
mobilization on cyclic AMP accumulation in
1321N1-hP2Y11 and CHO-hP2Y11 cells
Because the hP2Y11 receptor couples more eciently to
phospholipase C than to adenylyl cyclase, inositol lipid
hydrolysis is near maximal at concentrations of ATP that
only minimally increase cyclic AMP accumulation. Thus, the
downstream signalling eects of ATP-promoted inositol lipid
hydrolysis (i.e., intracellular Ca2+ mobilization and PKC
activation) potentially in¯uence cyclic AMP accumulation.
Therefore, we investigated the eects of both intracellular
Ca2+ mobilization and PKC activation on the capacity of
ATP to promote cyclic AMP accumulation in both 1321N1-
hP2Y11 and CHO-hP2Y11 cells. Cells were treated with
BAPTA-AM (50 mM) for 10 min to chelate intracellular
Ca2+, with the phorbol ester PMA (1 mM) for 20 h to down
regulate PKC, or with both agents, and cyclic AMP
accumulation was measured following challenge of the cells
with 300 mM ATP. In 1321N1-hP2Y11 cells, intracellular Ca2+
chelation decreased ATP-promoted cyclic AMP accumulation
by 41+5% (P50.01), whereas downregulation of PKC
resulted in a 57+1% decrease (P50.001; Figure 3A).
Combination of both treatments caused a slight but
signi®cant further decrease in cyclic AMP accumulation
(66+2%, P50.01) compared to PMA treatment alone. In
contrast, intracellular Ca2+ chelation had no eect on ATP-
promoted cyclic AMP accumulation in CHO-hP2Y11 cells,
whereas downregulation of PKC resulted in a 58+4%
decrease (P50.01) in ATP-promoted cyclic AMP accumula-
tion (Figure 4A). The eect of both treatments was not
signi®cantly dierent from PMA treatment alone.
To determine whether coupling of the hP2Y11 receptor to
inositol lipid hydrolysis is responsible for the potentiation of
cyclic AMP accumulation in these cells, we measured the
eects of intracellular Ca2+ chelation or down regulation of
PKC on other Gs-coupled receptors. Thus, we generated
1321N1 cells stably expressing the human D1 dopamine
receptor, which couples exclusively to Gs/adenylyl cyclase,
and determined the eects of intracellular Ca2+ chelation and
down regulation of PKC on dopamine-promoted increases in
cyclic AMP accumulation. In contrast to ATP-promoted
Figure 4 Eects of Ca2+ chelation and PKC down-regulation on
ATP-promoted cyclic AMP accumulation in CHO-hP2Y11 cells. (A)
Cells treated with BAPTA-AM (50 mM) for 10 min, PMA (1 mM) for
20 h, or a combination of both were challenged with buer, 300 mM
ATP, or 10 mM PGE1 for 10 min and cyclic AMP accumulation was
measured as described in Methods. (B) Concentration-response
curves of ATP for promotion of cyclic AMP accumulation in
untreated or PMA- (1 mM for 20 h) and BAPTA-AM-treated (50 mM
for 10 min) CHO-hP2Y11 cells. Data shown are the mean+s.d. of
triplicate assays from a representative experiment repeated three
times. **P40.01 relative to control responses.
Table 1 EC50 values and relative ecacies of adenine nucleotides and nucleotide analogues for promotion of IP production and cyclic
AMP accumulation in CHO-hP2Y11 cells
IP production Cyclic AMP accumulation
Nucleotide EC50 (mM) R.E. (%)
a EC50 (mM) R.E. (%) Ratio
b
ATP 3.6+1.3 100 62.4+15.6 100 17.3
ADP 50.1+20.6 60+4 NMc NM
ATPgS 1.2+0.4 95+4 23.2+6.5 84+7 19.3
ADPbS 3.7+0.7 72+1 25.9+0.4 78+6 7
2MeSATP 2.4+0.4 99+8 26.5+3.7 99+6 11
2MeSADP 14.6+3.2 61+6 NM NM
Results are presented as mean+s.d. of 3 ± 5 experiments. aR.E., relative ecacy, normalized by dividing the maximal response for each
nucleotide by the maximal response to 300 mM ATP and multiplying by 100. bRatio of EC50 for cyclic AMP accumulation to EC50 for
IP accumulation. cNM, not maximal, indicates the response did not reach the maximum at the highest concentrations of agonist.
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cyclic AMP accumulation in 1321N1-hP2Y11 cells, PMA/
BAPTA-AM treatment of 1321N1-hD1 cells had no eect on
dopamine-promoted cyclic AMP accumulation (Figure 3B).
In CHO-K1 cells, an endogenously expressed Gs-coupled
prostaglandin receptor was utilized to test the eects of
intracellular Ca2+ chelation and down regulation of PKC on
cyclic AMP accumulation. PGE2-promoted cyclic AMP
accumulation also was not aected in PMA/BAPTA-AM-
treated cells (Figure 4A). These data indicate the potentiation
of ATP-promoted cyclic AMP accumulation is due to the
coupling of the hP2Y11 receptor to inositol lipid hydrolysis.
To characterize further the in¯uence of PKC and
intracellular [Ca2+] on ATP-promoted cyclic AMP accumula-
tion, we compared the concentration-response curves of ATP
in vehicle versus PMA- and BAPTA-AM-treated 1321N1-
hP2Y11 and CHO-hP2Y11 cells. In 1321N1-hP2Y11 cells, the
response to 1 mM ATP was decreased by nearly 80% in
PMA/BAPTA-AM-treated cells, but the concentration-re-
sponse curve of treated cells did not reach a maximum and
an EC50 could not be calculated (Figure 3C). In CHO-
hP2Y11 cells, the maximal response to ATP was decreased by
*60% in PMA-treated cells, whereas the EC50 values were
not signi®cantly dierent from one another (Figure 4B).
We also investigated the eect of short term activation of
PKC on cyclic AMP accumulation in both cell lines.
Consistent with the eect of PKC downregulation, which
decreased cyclic AMP accumulation, activation of PKC by
short-term addition of PMA (1 mM, 10 min) signi®cantly
potentiated ATP-, PGE1-, and forskolin-promoted increases
in cyclic AMP accumulation in CHO-hP2Y11 cells (Figure
5A). To verify that receptor-stimulated intracellular Ca2+
mobilization and PKC activation could increase adenylyl
cyclase activity, cyclic AMP accumulation was measured in
1321N1-hD1 cells treated with dopamine alone or with
carbachol, which activates an endogenous M3 muscarinic
receptor coupled to Gq/phospholipase C (Figure 5B). M3
receptor activation alone had no aect on cyclic AMP levels,
whereas M3 receptor activation increased dopamine-stimu-
lated cyclic AMP accumulation by nearly 2 fold (P50.001),
consistent with the potentiating eects of PKC activation
and intracellular Ca2+ mobilization on adenylyl cyclase
activity.
Discussion
We show here that the hP2Y11 receptor, when exogenously
expressed in either 1321N1 or CHO-K1 cells, couples to both
phospholipase C and adenylyl cyclase with marked dier-
ences in eciency. That is, ATP promotes IP accumulation in
both cell lines with 15 fold greater potency than it promotes
cyclic AMP accumulation. In addition, other adenine
nucleotides promoted both second messenger responses in
CHO-hP2Y11 cells with similar dierences (7 ± 20 fold) in
potency. The marked dierences in EC50 values for agonist-
promoted IP and cyclic AMP accumulation of the hP2Y11
receptor contrasts with another dual-coupled P2Y receptor,
an avian p2y receptor that simultaneously activates phos-
pholipase C and inhibits adenylyl cyclase (Boyer et al., 1997;
2000). This avian p2y receptor couples with similar eciency
to both inhibition of adenylyl cyclase and activation of
phospholipase C.
The data reported here are dierent from those of
Communi and colleagues, who have reported that ATP has
either similar (Communi et al., 1997) or even greater
(Communi et al., 1999) potency at the hP2Y11 receptor for
promotion of cyclic AMP accumulation relative to inositol
lipid hydrolysis. However, in those studies IP accumulation
was measured in transfected 1321N1 cells, whereas cyclic
AMP accumulation was measured in transfected CHO-K1
cells. It was reported in Communi et al. (1999) that when
both IP and cyclic AMP accumulation were measured in the
same transfected 1321N1 cell line, ATP promoted cyclic
AMP accumulation with much lower potency than it
promoted inositol phosphate accumulation. Thus, the dier-
ences in potencies for promoting the two second messenger
pathways in the same cell line reported in Communi et al.
(1999) are similar to the data presented here, although no
data were shown and this observation was not investigated
Figure 5 Eects of acute PKC activation and intracellular Ca2+
mobilization on cyclic AMP accumulation in CHO-hP2Y11 cells and
1321N1-hD1 cells. (A) CHO-hP2Y11 cells were treated with either
vehicle or PMA (1 mM) for 10 min, and cyclic AMP accumulation
was measured following challenge with buer, 300 mM ATP, 10 mM
PGE1 or 30 mM forskolin for an additional 10 min. *P40.05,
**P40.01 relative to untreated responses. (B) 1321N1-hD1 cells
were challenged with either vehicle or dopamine (100 mM) for 10 min
in the presence or absence of carbachol (300 mM) and cyclic AMP
accumulation was measured. Data shown are the mean+s.d. of
triplicate assays from a representative experiment repeated three
times. ***P40.001 relative to dopamine alone.
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further. Moreover, the authors reported that CHO-K1 cells
transfected with the hP2Y11 receptor did not show signi®cant
enhancement of ATP-promoted IP accumulation over the
response observed in untransfected cells, making them
unsuitable to characterize the coupling to inositol lipid
hydrolysis in this cell line. Thus, no direct comparison of
EC50 values for agonist-promoted second messenger re-
sponses could be made. The lack of a signi®cant response
in transfected CHO-K1 cells contrasts with the data reported
here, in which ATP application to CHO-K1 cells expressing
the hP2Y11 receptor raised IP levels to 20 fold higher than
those in vector-infected cells. The reasons for these dierences
are not clear, but may be due to the dierent expression
systems or dierences in the parental cell lines used.
The EC50 of ATP for promoting IP accumulation in
1321N1-hP2Y11 cells in this study was 4 ± 8 fold greater
compared to previous studies (Communi et al., 1997; 1999).
Similarly, ADP was inactive in the earlier studies, but
increased IP levels here. This suggests greater receptor reserve
of the hP2Y11 receptor or an increase in its coupling to Gq/11
in the population of cells we used. ADP had no eect on
cyclic AMP levels in 1321N1-hP2Y11 cells, but this was
probably due to the much lower coupling eciency of the
hP2Y11 receptor to adenylyl cyclase in these cells and the
lower potency and ecacy of ADP compared with ATP.
Likewise, the ability of ADP to promote cyclic AMP
accumulation in CHO-K1 cells infected with hP2Y11
receptor, together with the greater potency of ATP for
promotion of inositol lipid hydrolysis in CHO-hP2Y11 versus
1321N1-hP2Y11 cells, is consistent with a higher level of
expression of the hP2Y11 receptor in CHO-K1 cells than in
1321N1 cells. Higher levels of expression of the hP2Y11
receptor in CHO-K1 cells than in 1321N1 cells may explain
the greater potency of ATP for promotion of cyclic AMP
accumulation than for IP accumulation reported in earlier
studies (Communi et al., 1999). The in¯uence of receptor
density on coupling eciency of the hP2Y11 receptor is
unknown, but possibly could be addressed with an inducible
expression system.
It is possible that the activity of ADP in our experiments
was due to either contamination of ADP stocks with ATP or
that ADP was enzymatically converted to ATP by ecto-
nucleoside diphosphokinase activity from UTP or CTP
released by the cells into the medium. However, we believe
this possibility to be unlikely, since ADP stocks were treated
with hexokinase and hexokinase also was included in the
assay medium. We have shown previously that these
precautions are sucient to eliminate ATP contamination
in ADP stocks and to prevent bioconversion in the assay
medium (Nicholas et al., 1996). Furthermore, we have shown
recently that ADP is a partial agonist for promoting Ca2+
mobilization in 1321N1-hP2Y11 cells under conditions that
minimize nucleotide metabolism and bioconversion (Qi et al.,
manuscript in preparation). Thus, ADP appears to be a
partial agonist at the hP2Y11 receptor.
We also show here that concomitant stimulation of inositol
lipid hydrolysis, which increases intracellular Ca2+ mobiliza-
tion and activates PKC, markedly potentiates the maximal
levels of cyclic AMP accumulation without changing agonist
potency. In 1321N1-hP2Y11 cells, both chelation of intracel-
lular Ca2+ and downregulation of PKC markedly inhibit
ATP-promoted adenylyl cyclase activity, whereas in CHO-
hP2Y11 cells, ATP-promoted adenylyl cyclase activity is
refractory to [Ca2+] but is decreased when PKC is down-
regulated. This eect is speci®c to the hP2Y11 receptor; cyclic
AMP accumulation promoted by Gs-coupled receptors that
do not stimulate inositol lipid hydrolysis, such as hD1
dopamine or PGE2 receptors, is not aected by BAPTA-AM
or chronic PMA treatment. In addition, cyclic AMP
accumulation promoted by these Gs-coupled receptors was
potentiated following acute treatment of cells with PMA or
following co-activation of an endogenous Gq-coupled
muscarinic receptor. The most parsimonius explanation of
these results is that receptor-promoted increases in intracel-
lular Ca2+ mobilization and/or PKC activation potentiates
adenylyl cyclase activity in 1321N1 and CHO-K1 cells.
Several studies have documented cross-talk between Gs-
and Gq-coupled receptors (Ho et al., 1988; Donaldson et al.,
1988; Alexander et al., 1992; Klinger et al., 1998). However,
these studies focused on the consequences of activation of
two distinct G protein-coupled receptors, one coupled solely
to phospholipase C and the other coupled solely to activation
of adenylyl cyclase. In contrast, with the hP2Y11 receptor
cross-talk between signalling pathways occurs following
activation of a single receptor.
The dierences in sensitivity to PKC down-regulation or
Ca2+ chelation in 1321N1 and CHO-K1 cells are likely due to
the dierent isoforms of adenylyl cyclase expressed in these
cells. For example, adenylyl cyclase types II, III, V, or VII
are stimulated by PKC, whereas types I, III and VIII are
stimulated by Ca2+ (Tang & Hurley, 1998; Cooper et al.,
1995) Thus, the type(s) of adenylyl cyclase expressed in a cell
line or tissue can have marked in¯uence on the maximal
levels of hP2Y11-promoted cyclic AMP accumulation. A
recent study in HL-60 cells (Suh et al., 2000), which
endogenously express the P2Y11 receptor, showed that acute
treatment with PMA potentiated dATP-, forskolin- and
cholera toxin-mediated increases in cyclic AMP accumula-
tion, suggesting that these cells express an isoform of adenylyl
cyclase that is potentiated by PKC. Thus, potentiation of
adenylyl cyclase in HL-60 cells by PKC is consistent with our
data in both CHO-K1 and 1321N1 cells.
There are relatively few examples of receptors that couple
to the activation of both phospholipase C and adenylyl
cyclase. These include receptors for the pituitary adenylyl
cyclase-activating polypeptide (PACAP; Spengler et al., 1993;
Pisegna & Wank, 1996), luteinizing hormone (LH; Guder-
mann et al., 1992), calcitonin (CT; Houssami et al., 1994),
thyrotropin (TSH; Van Sande et al., 1990), parathyroid
hormone (PTH; Abou-Samra et al., 1992) and three
tachykinins (substance P, substance K, and neuromedin K;
Nakajima et al., 1992). Interestingly, all of these receptors are
class 1b receptors, which recognize peptide hormones as their
cognate ligands (Bockaert & Pin, 1999). Although the hP2Y11
receptor is activated by small nucleotides, sequence analysis
indicates that P2Y receptors are more closely related to
peptide receptors than they are to receptors for small
molecules such as biogenic amines and adenosine (Lustig et
al., 1993). Thus, dual coupling to phospholipase C and
adenylyl cyclase may be con®ned to a small subset of class 1b
receptors.
These dual-coupled receptors also show dierent ecien-
cies in their coupling to cyclic AMP and IP accumulation. In
contrast to the P2Y11 receptor, the PACAP, LH, CT, and
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TSH receptors couple more eciently (6 ± 40 fold) to cyclic
AMP accumulation than to inositol lipid hydrolysis (Spengler
et al., 1993; Pisegna & Wank, 1996; Gudermann et al., 1992;
Oermans et al., 1996). However, the tachykinin receptors
showed similar coupling eciencies as the hP2Y11 receptor,
in which stimulation of inositol lipid hydrolysis occurred at
agonist concentrations 10 fold lower than for stimulation of
cyclic AMP accumulation (Nakajima et al., 1992). To date,
no studies have shown whether these dierences have any
functional relevance for the physiological activities of the
receptors.
In conclusion, the hP2Y11 receptor is coupled to both
phospholipase C and adenylyl cyclase, but is more eciently
coupled to phospholipase C. In addition, the capacity of ATP
to promote cyclic AMP accumulation in 1321N1-hP2Y11 and
CHO-hP2Y11 cells is markedly potentiated by mobilization of
intracellular Ca2+ and/or activation of PKC as a consequence
of coupling to Gq/phospholipase C.
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